Dr Manya Angley

Dr Manya Angley Director, Manya Angley Research & Consulting, SA

MM2016 Invited Speaker

Dr Manya Angley is an Adelaide-based registered pharmacist and accredited pharmacist. She held academic appointments (teaching and research) in the School of Pharmacy and Medical Sciences, University of South Australia from 1990 to 2010 and is currently an adjunct senior research fellow. In 2015 she was credentialed as an Advanced Practice Pharmacist. Her research has mainly focused on continuity of care and medication management in developmental disorders. Early in 2010 she established Manya Angley Research and Consulting (MARAC) which is an independent organisation that provides expertise in the design, implementation and evaluation of health and academic programs and services. Manya is a member of the SHPA Accredited Pharmacist Reference Group and the National Translational Research Collaborative Steering Committee.

In May 2012 she joined the team at East Adelaide Healthcare as a consultant pharmacist where she has worked closely with her medical colleagues to develop a collaborative model for the pharmacist’s role in a general practice. She also regularly conducts Home Medicines Reviews (HMR) for individuals with developmental disorders across Adelaide and in some regional areas.

General practice pharmacists in 3D: Designing, Defining & Delivering

Saturday 19 November, 1215-1254

Currently integration of pharmacists into general practice is relatively rare. When the Home Medicines Review (HMR) business rules were altered in October 2011 to enable direct HMR referrals, I made enquiries to East Adelaide Healthcare (EAHC), a large, metropolitan general practice about joining their team. After discussions with the practice’s principals I joined EAHC in May 2012 as a ‘practice pharmacist’, primarily to conduct HMRs. HMR interviews are always conducted in patients’ homes with remote access to the practice’s server so patients’ case notes can be viewed during home visits and from a home office.

Advantages of our ‘practice pharmacist’ model include:

1. The ease of communicating patient data within our private email system to refer and discuss as needed;
2. Access to patients’ notes enables more informed and specific medication management recommendations to be made and uptake is almost 100%;
3. Being a member of the practice team builds credibility with patients and patient satisfaction is high;
4. The practice pharmacist role serves as a conduit between the patient’s GP and their community pharmacy;
5. The practice pharmacist is ideally positioned to conduct timely post-discharge reviews; and
6. GPs value the fact that there is no conflict of interest between clinical pharmacy services and medication supply.

Disadvantages include:
1. Although access to patients’ notes lead to a superior HMR report it makes the review process more time consuming; and
2. Currently the only activity undertaken by a practice pharmacist that is Government funded is HMRs, via the Community Pharmacy Agreement (CPA), which limits the contributions practice pharmacists can make to team care.

As Australia’s population ages and healthcare becomes increasingly complex, the need for contributions from primary care pharmacists has never been greater. Government funding should be available beyond delivering medication reviews and should be independent of the CPA.